WO2006030898A1 - アルドース還元酵素阻害剤 - Google Patents
アルドース還元酵素阻害剤 Download PDFInfo
- Publication number
- WO2006030898A1 WO2006030898A1 PCT/JP2005/017153 JP2005017153W WO2006030898A1 WO 2006030898 A1 WO2006030898 A1 WO 2006030898A1 JP 2005017153 W JP2005017153 W JP 2005017153W WO 2006030898 A1 WO2006030898 A1 WO 2006030898A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- aldose reductase
- reductase inhibitor
- extract
- inhibitor according
- solvent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/49—Fagaceae (Beech family), e.g. oak or chestnut
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q1/00—Make-up preparations; Body powders; Preparations for removing make-up
- A61Q1/02—Preparations containing skin colorants, e.g. pigments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/02—Preparations for cleaning the hair
Definitions
- the present invention relates to an aldose reductase inhibitor. More specifically, the present invention relates to a food / beverage product or pharmaceutical product having a aldose reductase inhibitory action containing a solvent extract of a beech family Quercus.
- Nutritional satisfaction is the primary value of products in the food field, but in addition, taste-visual and olfactory impressions have also been pursued.
- additional values such as biological function regulation and homeostasis disturbance prevention have been demanded. This tendency is strong in luxury products, especially for alcoholic beverages, and red wine's biooxidative stress-inhibiting effect and Japanese sake lees' cell growth promoting effect are well known.
- the effect of red wine is derived from the grape seed coat, and grapes are also a product of the organism.
- Whiskey has a unique taste and visual 'olfactory merit by aging in oak barrels due to its manufacturing method, but this aging is done by extracting oak with distilled alcohol.
- this aging is done by extracting oak with distilled alcohol.
- the unique ingredients of oaks and carp plants contribute greatly to their characteristics.
- Aged whiskeys are therefore expected to have unique physiological effects derived from oak ingredients.
- diabetes it is known that complications (typically diabetic retinopathy, diabetic nephropathy, and diabetic neuropathy) lead to serious disease states.
- the enzyme involved in the exacerbation of this complication is aldose reductase.
- This enzyme is involved in a process that causes abnormal metabolism of the polyol metabolic pathway, which is one of the intracellular glucose metabolism pathways, and causes diabetic complications such as neuropathy. More specifically, glucose uptake in peripheral nerve Schwann cells, renal mensagum cells, vascular endothelial cells, retinal vascular pericytes, and crystalline epithelial cells in tissues that cause diabetic complications is insulin-independent.
- Intracellular glucose concentration rises in proportion to blood glucose level, and glycolytic initial enzyme becomes saturated under hyperglycemia, and glucose flows into the polyol pathway (Fig. 1).
- This glucose Sorbitol produced by the action of ludoose reductase accumulates in cells because of its slow metabolism. This accumulation increases intracellular osmotic pressure, which damages systematically and functionally.
- consumption of NADPH can cause oxidative stress because it makes it difficult to regenerate reduced dartathione.
- aldose reductase inhibitors are expected to be used as therapeutic agents for diabetic complications.
- the diabetic neuropathy treatment Epalrestat which is the only drug that has been put to practical use as this type of drug, may cause side effects of liver damage unless used under the control of a doctor. Or, there is a problem that it cannot be used on a daily basis.
- Non-Patent Literature l Folia Pharmacol. Jpn. (1998) 111; 137-145
- Non-Patent Document 2 Recent Res. Devel. In Agricultural & Biological Chem. (1997) 1; 147—1 60
- the present inventors aim at the preventive effect of lifestyle-related diseases, and in particular, search for whiskey or oak components for functions and components effective for physiological reactions related to diabetes.
- the subject of the present invention is derived from whiskey or a beech family Quercus genus plant (for example, oak) used for its production, and there is no problem with respect to stable supply with high safety and compliance.
- a beech family Quercus genus plant for example, oak
- a further subject of the present invention is the above-mentioned aldose reductase inhibitor, or diabetic complications, especially containing ellagic acid and Z or isoquercitrin found in the inhibitor as active ingredients.
- diabetic complications especially containing ellagic acid and Z or isoquercitrin found in the inhibitor as active ingredients.
- a further subject of the present invention is the aldose reductase inhibitor, or ellagic acid and Z Or to provide healthy foods and beverages and cosmetics suitable for the prevention and z or treatment of diabetic complications with the addition of isoquercitrin.
- whiskey contains an aldose reductase inhibitor, and the amount of the inhibitor component increases with the aging period of the whiskey. Therefore, the aldose reductase inhibitor is considered to have been extracted from the power of oak wood that makes barrels for ripening whiskey.
- the present invention is an aldose reductase inhibitor containing a solvent extract of a beech family Quercus.
- oaks are particularly preferred.Oaks referred to in the present invention are used as raw materials for barrels for production and storage of whiskeys, brandies, etc., among the plants of the genus Quercus.
- these oaks can be preferably used, and among these, white oak, common oak, triol oak and mizunara can be particularly preferably used.
- the parts used as raw materials are not particularly limited, and trunks, leaves, branches, crusts, flowers, berries and the like can be used. In addition, they may be used immediately after collection or after drying. If necessary, it can be processed by crushing, cutting, chopping, molding and the like. Chips, wood flour, barrels, etc. that can be used as processed products are examples of processed products. It is preferable to heat the barrel, such as baking the inner surface, before using it for solvent extraction. That's right.
- an aqueous solution of a lower alcohol can be preferably used.
- the lower alcohol include linear or branched alcohols having 1 to 4 carbon atoms (for example, methanol, ethanol, propanol, butanol, etc.). It is important that the concentration of the lower alcohol in the aqueous solution is a concentration at which an extract having a strong aldose reductase inhibitory action can be obtained. Specifically, the concentration of the lower alcohol in the lower alcohol aqueous solution is usually about 10 to : LOO volume%, preferably about 30-99 volume%.
- the extraction solvent may contain other components as long as the extraction efficiency is not significantly impaired.
- water-soluble components such as saccharides, salts or amino acids and various other solvents (for example, ethyl acetate, acetone) may be contained as desired.
- an aqueous ethanol solution obtained by mixing an industrial reagent with water may be used, or various alcohol products or work-in-process may be used.
- Good For example, brandy, whiskey, shochu, sake, beer, sparkling liquor, spirits, vodka or work in progress thereof can be mentioned.
- a product obtained by distilling an ethanol-containing material can be suitably used as the solvent.
- a product obtained by distilling an ethanol-containing product refers to a distillate obtained by distilling a solution containing ethanol.
- an ethanol-containing product obtained by saccharification and fermentation using malt, rice, grapes and the like as part of the raw material can be obtained by single distillation or double distillation.
- whiskey pre-storage liquor malt whiskey's original liquor-you pot, Glen Whiskey's original liquor-you make
- brandy pre-storage liquor nouvelle
- whiskey pre-storage raw alcohol and brandy pre-storage raw alcohol can be suitably used.
- the extraction conditions are preferably about half to 30 years at room temperature, but there is no substantial upper limit on the extraction time.
- the extraction method using a plant solvent used as a raw material in the present invention is not particularly limited, and is carried out by bringing a solvent that is not in contact with the plant raw material.
- a force for immersing the raw material in the solvent or a container such as a barrel may be formed using plant raw material and the solvent may be injected into the container. It may be stored at rest, or the extraction mode such as heating under reflux or immersion extraction may be appropriately set as desired according to known means. Extraction may be performed at room temperature or with warming.
- the extraction temperature is not particularly limited, it is preferably not more than the boiling point of the solvent in operation.
- the time required for extraction is usually about 30 minutes to 30 years, depending on temperature conditions and extraction method. However, there is no practical upper limit on the extraction time.
- the extract containing the aldose reductase inhibitor component is separated from the beech family Quercus plant, its processed product or its processed product according to means known per se.
- separation means include well-known means such as centrifugation and filtration.
- the extract may be used as it is as an aldose reductase inhibitor, or a concentrate or dried product (concentrated and dried product) of the extract may be used as an aldose reductase inhibitor. Concentration is performed under normal pressure or reduced pressure. Concentration may reduce the volume of the concentrate to about 5-70% by volume, preferably about 10-50% by volume.
- the dried product is obtained by evaporating the solvent from the extract containing the aldose reductase inhibitor component, preferably under reduced pressure.
- the solvent extract of the present invention includes a product obtained by further fractionating and purifying the extract obtained by the extraction by, for example, column chromatography.
- the solvent extract obtained in this way can be used as an extract after completion of the extraction operation, a concentrate obtained by partially removing the solvent of the extract, or a dry product obtained by removing all of the solvent. From the viewpoint of storage stability and ease of carrying, it is preferably used as a dried product.
- the solvent extract referred to in the present invention refers to these extracts, concentrates and dried products.
- the solvent extract may be used as an aldose reductase inhibitor as it is, and further, for example, an appropriate liquid such as acid titanium dioxide, calcium carbonate, distilled water, lactose, starch or the specific examples described in the following examples, or Solid excipients or bulking agents may be added to the aldose reductase inhibitor.
- the mixing ratio of the solvent extract in the aldose reductase inhibitor is not particularly limited. However, depending on the nature of the extract (extract, concentrate, or dried product), for example, about 0.01 to: It can be appropriately set within a range of% by mass.
- the aldose reductase inhibitor of the present invention may be prepared as it is in foods, beverages, cosmetics and pharmaceuticals, but is used as an additive or a compounding agent for foods, beverages, cosmetics and pharmaceuticals. May be.
- the additive or compounding agent for foods and beverages, cosmetics or pharmaceuticals referred to in the present invention is an additive or a compound usually used for foods, beverages, cosmetics or pharmaceuticals such as fragrances, pigments and antioxidants. This refers to a compounding agent mixed with a solvent extract. What is necessary is just to set a mixing ratio suitably.
- the mixing ratio is, for example, about 0.01 to: LOO wt%, preferably 0.1 to 80 wt%.
- additives or compounding agents for foods, beverages, cosmetics or pharmaceuticals used here include various additives described below.
- the amount to be added to foods and drinks, cosmetics, and pharmaceuticals when used as an additive or a compounding agent is not particularly limited, but is, for example, about 0.01 to: LOO wt% based on the solvent extract, preferably Can be appropriately set in the range of about 0.1 to 80% by weight.
- LOO wt% based on the solvent extract
- the properties of the extract are also considered.
- Foods and beverages produced using or blending with the aldose reductase inhibitor of the present invention include salmon, troches, gum, yogurt, ice cream, pudding, jelly, mizuyokan, alcoholic beverages, and coffee beverages.
- Juice, fruit juice beverages, carbonated beverages, soft drinks, milk, whey beverages, lactic acid bacteria beverages, etc. can be provided as foods and drinks with appropriate amounts of solvent extracts. These foods and drinks can be obtained according to conventional methods by blending various additives as necessary.
- the cosmetics referred to in the present invention include products called cosmetics and perfume products. When these products are provided, they are used in lotions, cosmetic creams, emulsions, foundations, lipsticks, hair styling products, hairdressing products. A suitable amount of solvent extract is added to non-oral cosmetics such as cosmetics, hair restorers, shampoos, rinses, and bath preparations, and oral cosmetics such as toothpastes, mouthwashes, mouthwashes, and oral fragrances. Cosmetic products can be prepared.
- These cosmetics include, for example, fats and oils such as vegetable oils, waxes such as lanolin and beeswax, hydrocarbons, fatty acids, higher alcohols, esters, various surfactants, pigments, fragrances, Vitamins, plant, animal extract ingredients, UV absorbers, antioxidants, antiseptics, bactericides, moisturizers (eg urea, hyaluronic acid), etc.
- fats and oils such as vegetable oils, waxes such as lanolin and beeswax
- hydrocarbons such as lanolin and beeswax
- fatty acids such as fatty acids, higher alcohols, esters
- various surfactants such as fatty acids, higher alcohols, esters
- pigments such as fatty acids, higher alcohols, esters
- various surfactants such as pigments, fragrances
- Vitamins such as plant, animal extract ingredients
- UV absorbers such as antioxidants, antiseptics, bactericides
- moisturizers eg urea,
- the aldose reductase inhibitor of the present invention is prepared or formulated into a pharmaceutical product, various additives are added as necessary, and an appropriate amount of a solvent extract is added to prepare the pharmaceutical product in various dosage forms.
- oral medicine such as tablets, capsules, granules, powders, syrups, extracts, etc., or ointments, eye ointments, lotions, creams, patches, suppositories, eye drops, nasal drops, injections, etc. It can be provided as a parenteral drug.
- These pharmaceuticals may be produced according to conventional methods using various additives. There are no particular restrictions on the additives used, and those commonly used can be used.
- Examples include solid carriers such as starch, lactose, sucrose, mannitol, carboxymethylcellulose, corn starch, inorganic salts, distillation Water, physiological saline, aqueous glucose solution, alcohol such as ethanol, liquid carriers such as propylene glycol and polyethylene glycol, various animal and vegetable oils, oily carriers such as white petrolatum, paraffin and waxes.
- solid carriers such as starch, lactose, sucrose, mannitol, carboxymethylcellulose, corn starch, inorganic salts, distillation Water, physiological saline, aqueous glucose solution, alcohol such as ethanol, liquid carriers such as propylene glycol and polyethylene glycol, various animal and vegetable oils, oily carriers such as white petrolatum, paraffin and waxes.
- aldose reductase inhibitor of the present invention when preparing foods, drinks, cosmetics or pharmaceuticals using the aldose reductase inhibitor of the present invention, other aldose reductase inhibitors, melanin production inhibitors such as ascorbic acid, hydroquinone, etc. , Kojic acid, placenta extract, arbutin, or extract components of plants such as fire spines, quinonine, quince, cypress, jasmine, and cay pilpy.
- plant extract components and the solvent extraction of the present invention The blending ratio of the product is not generally defined, but is usually about 1: 9 to 9: 1 by weight.
- the active ingredient of the aldose reductase inhibitor in the solvent extract of the beech family Quercus belongs to the following formula:
- the isoquercitrin represented by these is contained.
- the fact that ellagic acid has an aldose reductase inhibitory action is a new finding.
- Ellagic acid and isoquercitrin are aldose reductase inhibitory active ingredients that have been found so far, and there may be other inhibitory active ingredients in the solvent extract of the beech family Quercus. It will remain.
- the ellagic acid represented by the above formula, optionally isoquercitrin represented by the above formula, and optionally further aldose reductase inhibitory components are activated.
- an aldose reductase inhibitor contained as a component. Any of the compounds of the above formula may be present in the aldose reductase inhibitor of the present invention as a precursor that decomposes in vivo to produce the compound of the above formula! /.
- the aldose reductase inhibitor of the second aspect of the present invention can also be used for the preparation of foods, beverages, cosmetics or pharmaceuticals, just like the aldose reductase inhibitor of the first aspect. .
- an aldose reduction that can be used on a daily basis for the prevention or treatment of diabetic complications, with which there is no problem with a stable supply with high safety and sufficient compliance.
- Enzyme inhibitors were provided.
- the aldose reductase inhibitor of the present invention can be used at the time of oral administration when an aqueous ethanol solution is used as a solvent, or when an oak with abundant experience in eating and drinking with an extract is used as a raw material plant. Since it is excellent in safety, it can be suitably used as a food / beverage product, oral medicine, or oral cosmetic for the prevention or treatment of diabetic complications. Therefore, whiskey and brandy, or concentrates and dried products thereof can be suitably prepared as food / beverage products, oral medicines and oral cosmetics as solvent extracts.
- FIG. 1 shows the relationship between aldose reductase and a polyol metabolic pathway.
- FIG. 2 is a list of various compounds contained in whiskeys and oaks whose aldose reductase inhibitory action was examined in the present invention.
- FIG. 3 is a graph comparing the aldose reductase inhibitory action of various luxury products.
- FIG. 4 is a graph showing the results of examining the action of aldose reductase inhibitors by alcohol.
- FIG. 5 is a graph showing the relationship between the aging period of whiskey and the inhibition rate of aldose reductase.
- Aldose reductase is a method already published in the paper by pig eyes (Recent Res. Devel. In Agricultural & Biological Chem. (1997) 1; 147-160, p. 148, see “Preparation of Lens Aldose Reductase” Recombinant human aldose reductase was purchased from Wako Pure Chemicals, reacted with substrate (Dariceraldehyde) and coenzyme (NADPH), and measured NAD PH consumption (oxidation rate) at 340 nm (For details on the method for measuring aldose reductase activity, see Recent Res. Devel. In Agricultural & Biological Chem. (1997) 1; pp. 149, pp. 149, “Assay of Reductase Activity J”).
- a single castus whiskey (one barrel strength whiskey stock solution) with different ripening periods was added to the reaction solution of aldose reductase, and the relationship between the ripening period and aldose reductase inhibition was investigated.
- Single castus was prepared so as to be 1% of the total reaction solution.
- 60% EtOH was used at 1%.
- the control AR inhibition% was zero.
- Figure 5 shows the relationship between the ripening period and the inhibition rate.
- Example 3 Aldose reductase inhibitory component in whiskey Spanish oak is also called common oak and its scientific name is Quercus robur L. American oak is also called white 'oak and its scientific name is Quercus alba and Mizunara 's scientific name is Quercus crispula BLUME.
- American oak is also called white 'oak and its scientific name is Quercus alba and Mizunara 's scientific name is Quercus crispula BLUME.
- the compounds represented by the structural formula in Fig. 2 were obtained, and the aldose reductase inhibitory action was examined.
- ellagic acid showed an inhibitory action
- test system described immediately before Example 1 showed an inhibitory activity of 65% at a concentration of 100 M.
- the Quercus genus plant contains tannin having many complicated structures. Since these are adsorbed to proteins, aldose reductase inhibition is also considered. In addition, isoquercitrin has been found in Q. ro bur, and such flavonoid glycosides have an aldose reductase inhibitory action. Considering the presence or absence of flavonoids and coumarins Example 4
- a pharmaceutical product containing the solvent extract of the present invention was produced by the following method.
- the ethanol concentration is added to 60 volume 0/0 aqueous 30L, and stirred for 3 hours at 60 ° C.
- the solvent of the obtained extract was also removed, and 15 g of white oak extract (dried product) was obtained.
- the above tablets were pulverized, sized, and sieved to obtain 20-50 mesh granules.
- a white oak extract was prepared in the same manner as in Example 4, and various foods and drinks containing the solvent extract of the present invention were produced with the following composition.
- the white oak extract (dried product) in the following composition was obtained in Example 4.
- composition (Parts by weight) Alavia gum 6 Glucose 73 White oak extract (Dried product) 0.05 Dipotassium phosphate 0.2 Dipotassium phosphate 0.1 Lactose 17 Fragrance 0.1 Magnesium stearate 3.55 Total amount 100
- composition (Parts by weight) Gum base 20 Calcium carbonate 2 Stepioside 0. 1 White oak extract (Dry product) 0.05 Lactose 76. 85 Fragrance 1 Total 100 [0047] [Table 5]
- composition Parts by weight Granulated sugar 32. 0 Minamata 20. 0 Powdered milk 40. 0 Hardened oil 4. 0 Salt 0. 6 Fragrance 0. 02 Water 3. 22 White oak extract (Dry product) 0. 16 Total 100
- composition Parts by weight Milk 47. 51 Whole egg 3 1. 9 White sugar 1 7. 1 Water 3.4 White oak extract (Dry product) 0.09 Total 100
- composition (Parts by weight) Akafangan 24.8 Powder agar 0. 3 Salt 0. 1 White sugar 24.9 White oak extract (Dry product) 0. 1 Water '49. 8 Total 100
- composition Parts by weight Frozen Condensed Satsuma Orange Juice 5 Fructose Glucose Liquid Sugar 1 1 Quenic Acid 0.2 2 Monoascorbic Acid 0.02 White Oak Extract (Dry) 0. 05 Fragrance 0. 2 Dye 0. 1 Water 83. 43 Total 100
- Lactic acid bacteria beverage
- composition (Parts by weight) Granulated sugar 8.0 Skim milk powder 5. 0 Caramel 0. 2 Coffee extract 2. 0 Fragrance 0. 1 Polyglycerin 0. 05 Fatty acid ester
- a white oak extract was prepared in the same manner as in Example 4, and various cosmetics containing the solvent extract of the present invention were produced with the following composition.
- the white oak extract (dried product) in the following composition was obtained in Example 4.
- composition (Parts by weight) Beeswax 2.0 Stearino alcohol 5. 0 Stearic acid 8. 0 Squalane 10. 0 Self-emulsifying propylene glycol 3.0 Mono stearate
- composition (Parts by weight) Stearic acid 2. 0 Cetanol 1.5 Petrolatum 3. 0 Lanolin ananolol 2. 0 Liquid paraffin 10. 0 Polyoxyethylene monooleic acid 2. 0 ester (10 E. O.)
- composition (Parts by weight) Stearic acid 2.4 Propylene monostearate 2.0 Glycol
- composition (Parts by weight) Ethanonore 70.0 Senpri extract 0.2 Vitamin E 0.2
- Makoto (Fine heavy fine 4 o 81 parts) Amount s I Alkyl ether sulfuric acid 16. o09 o 1 Sodium (AES— Na) Diethanolamide lauric acid Propylene dallicol
- composition (Parts by weight) Stearyldimethyl chloride 4 Benzenoreammonium
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Diabetes (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Birds (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Vascular Medicine (AREA)
- Neurology (AREA)
- Medical Informatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
- Cosmetics (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004272039A JP2006083138A (ja) | 2004-09-17 | 2004-09-17 | アルドース還元酵素阻害剤 |
JP2004-272039 | 2004-09-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006030898A1 true WO2006030898A1 (ja) | 2006-03-23 |
Family
ID=36060145
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/017153 WO2006030898A1 (ja) | 2004-09-17 | 2005-09-16 | アルドース還元酵素阻害剤 |
Country Status (2)
Country | Link |
---|---|
JP (1) | JP2006083138A (ja) |
WO (1) | WO2006030898A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017073704A1 (ja) * | 2015-10-28 | 2017-05-04 | サントリーホールディングス株式会社 | アルコールテイスト飲料 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4211771A (en) * | 1971-06-01 | 1980-07-08 | Robins Ronald K | Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide |
JP2004516257A (ja) * | 2000-12-21 | 2004-06-03 | ザ キグリー コーポレーション | 糖尿病性神経障害の治療に対する組成物及びその方法 |
-
2004
- 2004-09-17 JP JP2004272039A patent/JP2006083138A/ja active Pending
-
2005
- 2005-09-16 WO PCT/JP2005/017153 patent/WO2006030898A1/ja active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4211771A (en) * | 1971-06-01 | 1980-07-08 | Robins Ronald K | Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide |
JP2004516257A (ja) * | 2000-12-21 | 2004-06-03 | ザ キグリー コーポレーション | 糖尿病性神経障害の治療に対する組成物及びその方法 |
Non-Patent Citations (8)
Also Published As
Publication number | Publication date |
---|---|
JP2006083138A (ja) | 2006-03-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW200529864A (en) | Method for producing maca extract | |
JP2001270881A (ja) | プロアントシアニジン含有組成物 | |
JP5420136B2 (ja) | 抗老化剤 | |
JP2700958B2 (ja) | 甜茶抽出物を有効成分とする医薬並びにこれを配合した食品および化粧品 | |
CA2319967A1 (en) | Compositions containing proanthocyanidin and a vitamin b6 derivative or a salt thereof | |
TWI527588B (zh) | 美白劑 | |
KR102283527B1 (ko) | 곡류 발효 추출물을 유효성분으로 함유하는 화장료 조성물 | |
JP7121757B2 (ja) | 新規なクエルセチン系化合物を含む美白用組成物 | |
WO2006030898A1 (ja) | アルドース還元酵素阻害剤 | |
JP7453783B2 (ja) | 成分含量が変化した緑茶抽出物を含む皮膚美白用又は皮膚しわ予防又は改善用組成物 | |
KR101685829B1 (ko) | 항산화 활성이 증진된 겨우살이 추출 발효물의 제조방법 | |
JP2011184457A (ja) | 抗老化剤 | |
JP2006083131A (ja) | アルドース還元酵素阻害剤 | |
JP7179025B2 (ja) | 後発酵茶由来の新規なケンペロール系化合物を含む抗炎症組成物 | |
JP2001158739A (ja) | プロアントシアニジンとビタミンb6誘導体またはその塩とを含有する組成物 | |
JP4988166B2 (ja) | キサンチンオキシダーゼ阻害剤 | |
KR102564361B1 (ko) | 진세노사이드 f5를 포함하는 탈모 방지 또는 육모 촉진용 조성물 | |
JP7071406B2 (ja) | 新規なクエルセチン系化合物を含む抗炎症組成物 | |
KR102239470B1 (ko) | 항산화 활성이 증진된 발효 흑미 추출물을 유효성분으로 함유하는 피부 미백용 조성물 | |
KR102544546B1 (ko) | 솔잎을 포함한 식물 잎 추출물의 혼합물을 유효성분으로 함유하는 항비만용 조성물 | |
JP6974450B2 (ja) | 後発酵茶由来の新規なケンペロール系化合物を含む認知機能改善用組成物 | |
JP7121758B2 (ja) | 後発酵茶由来の新規なケンペロール系化合物を含む美白用組成物 | |
KR20010091310A (ko) | 숙취해소용 음료조성물 및 그 제조방법 | |
KR20170046028A (ko) | 미숙과 추출물을 포함하는 미백용 조성물 | |
JP2023123798A (ja) | アクアポリン3発現促進用組成物及びその使用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |